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 Lysophosphatidic acid (LPA) is a bioactive lipid with a plethora of biological functions, 
including roles in cell survival, proliferation, and migration. Although high-performance liquid 
chromatography electrospray ionization tandem mass spectrometry (HPLC ESI-MS/MS) 
technology has been used to measure the levels of LPA in human blood, serum and plasma, 
current methods cannot readily detect the minute levels of LPA from cell culture. In this study, a 
xi 
 
novel HPLC ESI-MS/MS method with enhanced sensitivity was developed which allows 
accurate measurements of LPA levels with a limit of quantitation at approximately 10 
femtomoles. The method was validated by quantitation of LPA levels in the media of previously 
characterized cell lines ectopically expressing autotaxin. Autotaxin overexpression 
induced an increase in several subspecies of LPA while others remained unchanged. Lastly, this 
HPLC ESI-MS/MS method was validated via biological assays previously utilized to assay LPA 
production. Hence, this new HPLC ESI-MS/MS will allow researchers to measure in vitro LPA 
levels and also distinguish between specific LPA subspecies for the delineation of individual 
biological mechanisms. 
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Introduction 
 
1.1 Discovery of the Biological Activity of LPA 
 Lysophosphatidic acid (LPA) is a glycerophospholipid is composed of a single, variable 
length acyl chain, a glycerol backbone and a phosphate head group.1 LPA had been known as a 
key lipid precursor for several decades, but the importance of LPA as a signaling molecule was 
not discovered until the mid-1980s. It was at this time when exogenous LPA was found to be the 
best and most potent Ca
2+
 mobilizing agonist and mitogen for quiescent fibroblasts.2 In 1990, 
Jalink et. al., showed that LPA concentrations in the low nanomolar range were sufficient to 
initiate the mobilization of Ca
2+
 across the plasma membrane.3 These studies showed the growth-
factor-like characteristics of LPA and that LPA had characteristics of a receptor ligand in that it 
was active well below its critical micelle concentration and displayed a dose-response 
relationship.2
,3 The study also demonstrated that the functions of LPA were cell-type specific, 
could not be recapitulated by other glycerolipids, and that LPA acted on the outer portion of the 
plasma membrane.2,3 These observations led to the conclusion that extracellular LPA interacts 
with specific receptors on the plasma membrane to initiate downstream signaling cascades.  
 
1.2 LPA Receptors 
 In 1996, the first G-protein coupled receptor (GPCR) specific for LPA was discovered. 4 
In this study, Hecht et. al. showed the overexpression of the vsg-1 gene resulted in increased cell 
rounding when treated with serum or LPA alone but did not increase when treated with other 
phospholipids.4 This lead to the classification of the protein product of vsg-1 as a LPA specific 
GPCR and the subsequent designation of this protein as LPA1. Shortly thereafter, two other LPA 
GPCRs were discovered based on sequence homology and were subsequently named LPA2 and 
2 
 
LPA3.
5-7 LPA1-3 are classified as members of the 'endothelial differentiation gene' (EDG) family. 
More recently, two additional GPCR specific for LPA have been discovered and named LPA4 
and LPA5.
7-9 LPA4 and LPA5 only share roughly 20% sequence homology to the EDG family 
receptors and are more closely related to the members of the purigenic receptor family. 
Therefore, they have been classified as members of the 'purinergic' (P2Y) receptors.10 Although 
the LPA receptors have varying sequence homologies, they are all Type1, rhodopsin-like GPCRs 
that contain seven transmembrane alpha helices and couple to distinct heterotrimeric G-protein 
subtypes.7 It is currently believed that there may be up to four more LPA specific receptors, but 
more research is necessary to properly characterize these receptors. The distinct coupling of the 
established LPA receptors and G-protein subtypes is depicted in Figure 1. 
 All of the established LPA receptors play important physiological roles. By activating 
GPCRs, LPA initiates the downstream signaling cascades depicted in Figure 1. These signaling 
cascades have important physiological functions that are outlined in Table 1 and Figure 1. As 
these figures clearly demonstrate, LPA plays a variety of important roles that affect normal 
biological functions. Since LPA plays many vital roles in human physiology, the dysregulation 
of LPA production or binding ability to LPA receptors can result in a variety of pathological 
conditions, a sampling of which are listed in Table 2.  
3 
 
 
Figure 1: LPA Receptors and Signaling Pathways 
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Table 1: Physiological Roles of LPA Signaling (adapted from 11) 
  
System Phenotype Roles for LPA signaling
Immune Dentritic cell function Maturation, chemotaxis
T cell functions Chemotaxis, apoptosis, trafficking, 
cytokine production
Vascular Vasoregulation Hypertension, endothelial cell death, loss 
of vascular integrity
Vasculogenesis, Angiogenesis Vasculature maintenance
Reproductive Embryo implantation Timing and spacing of implantation
Spermatogenesis Sperm motility, survival factor for germ 
cell
Nervous Growth/development Proliferation and differentiation of neural 
progenitor cells, neuronal survival, 
astrocyte proliferation, neurogenesis
Morphology Synapse formation, morphological 
changes in neurons and astrocytes
Myelination Differentiation of oligodendrocytes, 
Schwann cell proliferation, survival, and 
morphological changes
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Table 2: Pathophysiological Conditions Associated with LPA Dysregulation (adapted from 11) 
 
  
Cancer invasion and migration
Osteoarthritis
Pulmonary fibrosis
Renal fibrosis
Hepatic fibrosis
Impaired wound healing
Atherosclerosis
Obesity
Asthma
Nerve injury
Neuro-inflammation
Human pathological conditions associated with LPA dysregulation
Schizophrenia
Developmental delay
Bipolar disorder
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1.3 LPA Synthesis 
 There are several methods of LPA synthesis (Figure 2), but the major pathways of LPA 
production are the cleavage of an acyl chain from phosphatidic acid (PA) via a phospholipase or 
the removal of a choline from lysophosphatidylcholine (LPC) by autotaxin.12-14 PLA1 can cleave 
an acyl chain from the sn-1 position of PA to produce LPA while PLA2 can cleave an acyl chain 
from the sn-2 position of PA to produce LPA.13 Although PLA1 and PLA2 can synthesize LPA, 
the major source of LPA production  is the cleavage of a choline group from LPC by the enzyme 
autotaxin. Autotaxin is synthesized a prepro-enzyme that is proteolyzed by furin-mediated 
cleavage and secreted as an activated glycoprotein.15
,16 Originally identified as an autocrine 
motility factor secreted by melanoma cells, the discovery of the lyso-PLD function of autotaxin 
led to a better understanding of LPA production and function. 15, 17-19 The generation of LPA by 
autotaxin occurs by the hydrolysis of the choline group at the sn-3 position of 
lysophosphatidylcholine (LPC). The human gene that encodes autotaxin, ENPP2, contains 27 
exons and has been shown to form three alternatively spliced products.16
,20 ATXα, also referred 
to as ATXm, is a 915 amino acid protein that lacks exon 21 from ENPP2 gene that was 
originally cloned from human melanoma cell line A2058.21 ATXβ, also referred to as ATXt, is a 
863 amino acid protein that lacks both exons 12 and 21 from ENPP2 gene and was originally 
reported in human tetracarcinoma cells.22 A third, less prominent isoform, ATXγ, also known as 
PD-1α, lacks exon 12 and seems to be brain-specific.23 While the ability of autotaxin to produce 
LPA has been widely established, the specific LPA species produced by autotaxin isoforms is 
not well understood. Furthermore, the differential biological functions for the individual LPA 
subspecies have not been examined, mainly due to a lack of reliable method to analyze and 
quantitate LPA subspecies in vitro.  
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Figure 2: Routes of LPA Production. (H - head group, P - phosphate) 
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1.4 Lipid Extractions 
 Due to their wide variety of characteristics, no single extraction technique is sufficient for 
the separation of lipids from biological samples. Extractions protocols should be optimized to 
achieve most accurate and highest recovery for the individual lipid of interest.  The classical lipid 
extraction protocols are liquid-liquid extractions in which lipids separate into the more apolar 
solvent. The most common lipid extraction technique was originally devised by Folch, et. al., in 
1956 and involves a liquid-liquid extraction using a 2:1 ratio of chloroform:methanol.24 Most 
lipids, due to their hydrophobic character, will separate into chloroform phase since it is less 
polar than the methanol phase. Bligh and Dyer developed an adaptation of the Folch method to 
reduce solvent consumption with the separation again based on the polar character of the 
solvents.25 The Bligh-Dyer technique utilizes a chloroform:methanol:water extraction in the ratio 
of 1.25:2.5:1 with a centrifugation step to aid in phase separation. Lipids will again separate into 
the less polar, chloroform layer.  
 Numerous adaptations have been made to the Folch and Bligh-Dyer methods for the 
extraction of particular lipid classes. One such adaptation was made by Merrill et. al., for 
efficient extraction of sphingolipids. This method utilizes a single phase 
chloroform:methanol:water solvent combination and an overnight incubation at 48°C in order to 
account for the differing polarity among sphingolipids.26 Although lipid-specific adaptations of 
the Folch and Bligh-Dyer methods have been the common standard for multiple generations, 
many other lipid extractions have recently been popularized, including supercritical fluid 
extractions, single solvent extractions, and solid phase extractions (SPE). 
 Supercritical fluids are gases that approach the density of liquids but have the ability to 
diffuse like a gas. Due to its apolar character, supercritical carbon dioxide has been used 
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efficiently for the extraction of lipids.27 Although supercritical liquid extractions are 
environmentally friendly and can be easily established with simple laboratory apparatus, the 
extraction protocol has yet to become a widely used method of lipid extraction. Single solvent 
extraction techniques using solvents such as methanol, ethyl acetate, acetonitrile, and methyl 
tert-butyl ether have gained popularity because of the simple dilution and centrifugation protocol 
they entail.28 These extractions, however, may not provide significant lipid recovery from 
samples that contain very low levels of the lipid being analyzed, particularly in vitro samples. 
SPE extractions are based on principles of column chromatography where sample is separated 
based on its interaction with a stationary phase. SPE lipid extractions typically entail silica-based 
columns as stationary phases in order to separate lipids from the more hydrophilic molecules 
based on the hydrophobic interactions with the stationary phase.29 While SPE can provide 
remarkable recovery of certain lipid classes, the necessity of a separate SPE column for each 
sample can become economically unfeasible. As detailed above, no single extraction is sufficient 
for all lipids and therefore, several techniques should be tested for the optimal extraction of the 
specific lipid of interest. 
 
1.5 Lipidomics  
 Numerous detection and quantitation methods have been utilized for lipid analysis. After 
lipids have been extracted from samples, they must be further separated for accurate analysis. A 
classical technique for lipid separation is thin layer chromatography (TLC), a method that 
separates compounds based on capillary action in response to their interaction with the stationary 
phase.30. High-performance liquid chromatography (HPLC) has replaced TLC as the preferred 
method of lipid separation in recent generations.29 HPLC is similar in principle to TLC, as both 
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techniques separate lipids based on interaction with a stationary phase, but HPLC has proven to 
be a more versatile and more efficient method of separation. One advantage of HPLC separation 
of lipids is the ability to quickly and easily utilize different types of stationary phases for 
different categories of separation. In normal phase HPLC, lipids are separated based on head 
group interaction with a polar stationary phase and elution with a solvent gradient shifting from 
apolar to polar. This combination of stationary phase and solvent conditions allows for effective 
separation of lipid classes based on the charge of the molecule. Reverse phase chromatography 
separates lipids using apolar stationary phase and a solvent gradient that shifts from polar to 
apolar. This allows for accurate separation of lipid species based on the degree of hydrophobic 
interaction of the sample with an apolar stationary phase. The combination of normal and reverse 
phase HPLC in tandem allows for even greater discrimination of lipids based first on the charged 
head group and then on hydrophobic acyl chain length.31 The flexibility, increased sensitivity, 
and greater technical ease have led to HPLC becoming the preferred method of lipid separation. 
 Following extraction and separation, lipids can be detected using ultraviolet detection, 
immunoassays, radiolabelling, and mass spectrometry. If a lipid contains a chromophore, such as 
a conjugated double bond system, it can be measured using ultraviolet detection. In this detection 
method, chromatographic solvents selected must not absorb in the ultraviolet range. Although 
ultraviolet detection can be extremely sensitive, its limitations include the fact that it is more 
qualitative than quantitative in nature and the limitations on chromatographic solvent 
conditions.32 Immunoassays for specific lipid species are used, but are limited because they are 
not a direction detection method, are time-consuming and expensive, and are not available for all 
lipids. Radiolabelling using 
32
P has long been a common method of lipid measurement.33 TLC or 
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HPLC coupled to a radiation detector has been effectively used to analyze lipids, but 
radiolabelling is labor intensive and is of a more qualitative than quantitative nature. 
 The rapid advances in mass spectrometric technology in the past two decades have 
revolutionized the quantitative analysis of lipids. Mass spectrometry provides analysis of 
compounds based on the mass-to-charge ratio (m/z) of charged particles. The general schematic 
of mass spectrometric analysis of lipids proceeds in the following manner: the sample of interest 
is ionized and vaporized, then separated based on m/z by electromagnetic fields. The ions are 
then detected and processed to produce mass spectra that are used to provide accurate analysis. 
Although there are many instrument variations of mass spectrometers, the equipment necessary 
consists of a ion source, a mass analyzer, and a detector. The ion source is responsible for 
producing ions from the vaporized sample which then proceed to the mass analyzer for sorting 
by electromagnetic fields. A detector then measures the amount of ions present to produce a 
mass spectrum.31 
 There are several ionization sources and mass spectrometer combinations commonly used 
for lipid analysis. Matrix-assisted laser desorption ionization coupled to a time-of-flight 
spectrometer (MALDI-TOF) is one method commonly used for lipid analysis.. During MALDI-
TOF analysis, samples are mixed with a chemical matrix and dried onto a plate. A laser is then 
used to ionize the sample, and the ions are introduced into a TOF mass spectrometer. The TOF 
mass spectrometer measures the amount of time it takes from injection until the ions reach the 
detector to produce a mass spectrum. Although MALDI-TOF provides very high sensitivity and 
rapid sample analysis, matrices can often produce high background signal, making quantitative 
measurements unreliable.34 MALDI-TOF is therefore used primarily for qualitative analysis. 
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 The most widely regarded methods for quantitative lipid analysis are direct injection into 
a mass spectrometer, also called shotgun lipidomics, or injection into a mass spectrometer 
following HPLC separation.31 A shotgun lipidomics approach involves a direct injection of 
sample into the mass spectrometer, commonly using a syringe which is placed into a syringe 
pump to introduce the sample into the spectrometer at a steady rate in order to provide a steady 
signal.29 The sample then undergoes mass spectrometric analysis as outlined in the preceding 
paragraph. While shotgun lipidomics is simple and quick, it is inappropriate for many samples 
because it may cause mass spectrometer contamination, signal reduction, and ion interference. It 
also does not efficiently separate lipid species and causes other issues that would make 
quantitative analysis of specific species unreliable. Thus, shotgun lipidomics has primarily been 
used as a screening tool for identification of lipids in a sample rather than for quantitation of 
lipid species.34 
 The preferred method of lipid quantitation is injection into a mass spectrometer following 
HPLC separation.29 Samples undergo extraction and HPLC separation as detailed previously and 
are introduced into the mass spectrometer. This provides a sample which contains few 
contaminants and thereby increases sample throughput for the instrument. It also provides the 
ability to distinguish lipid species based on the retention time on the HPLC column.31 Coupling 
of HPLC to a mass spectrometer capable of performing tandem mass spectrometric analysis has 
become the common standard for accurate lipid quantitation. Tandem mass spectrometry 
(MS/MS) is method of analysis that detects compounds based on the principle of measuring the 
transition of a precursor ion of interest to a product fragment. A schematic demonstrating HPLC 
ESI-MS/MS using a triple quadrupole mass spectrometer in multiple reaction monitoring mode 
(MRM) is depicted in Figure 3. In this method of lipid quantitation, HPLC separation is 
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performed and then the sample is introduced into the mass spectrometer. Ionization is performed 
by an electrospray source which then focuses a tight beam of ions for progression into the Q0 
quadrupole. The ions are taken via vacuum into the Q0 quadrupole where they are trapped for 
progression into the Q1 quadrupole mass filter. The Q1 quadrupole scans and selects for a 
precursor ion. The selected precursor ions progress from Q1 quadrupole mass filter into the Q2 
collision cell where they are fragmented to create a product ion that is selected in the Q3 mass 
filter. These product ions are then measured by the detector, and a spectrum is generated. 
MS/MS uses the measurement of the distinct transition from precursor to product ion to provide 
accurate quantitation for compounds of interest. By selecting the transitions corresponding to 
individual lipid species and subspecies, HPLC ESI-MS/MS provides the most sensitive and 
accurate lipid quantitation method commonly used in modern research. 
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Figure 3: HPLC ESI-MS/MS Diagram 
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1.6 HPLC ESI-MS/MS Analysis of LPA 
 A variety of HPLC ESI-MS/MS methods have been developed to undertake LPA 
measurements from tissue, blood, plasma, and serum samples, but most are specific for 
separation and detection of LPA with little to no application in the detection of other lipid 
classes. Additionally, most of these methods demonstrate poor quality peaks or inadequate 
separation.35
,36 Some methods have even required pre-separation of LPA using thin-layer 
chromatography.37,38 There are also methodological issues for the extraction of LPA in these 
reported protocols as most have relied on adapted Bligh-Dyer techniques with the use of very 
low pH conditions, which may lead to the degradation of LPC to LPA and provide artificially 
inflated LPA measurements.36, 39 Even after acidic extractions, the limit of quantitation for LPA 
using these mass spectrometric methods have been in the low picomole or high femtomole range. 
37,39 While this sensitivity is adequate for quantitation for the high LPA levels of in vivo 
biological samples, greater sensitivity as well as a reliable, non-volatile pre-separation and 
accurate extraction protocol are required for in vitro LPA measurements. 
 
1.7 Project Objective 
 The objective of this study was to develop a HPLC ESI-MS/MS method for in vitro LPA 
quantitation  while avoiding the induction of artificially enhanced LPA levels from acidic 
extraction protocols. Additionally, the separation and detection utilized for LPA was designed 
for capability with the separation and detection of many other lipid classes. The method was 
validated for in vitro use by demonstrating increased levels of LPA in autotaxin overexpressing 
ovarian cancer cell lines. The biological role of these increased LPA levels was further validated 
using previously established proliferation and migration assays for measuring the levels of this 
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bioactive lipid. This novel HPLC ESI-MS/MS method will provide researchers with the ability to 
measure in vitro LPA levels as well as provide a more sensitive and accurate method for LPA 
quantitation in biological samples.  
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Materials and Methods 
 
2.1  Materials  
 SKOV3-Zeo, SKOV3-ATX, DOV13-Zeo, and DOV13-ATX cell lines were established 
by transfection of SKOV3/DOV13 cells with pcDNA3.1/Zeo or pcDNA3.1/Zeo-ATX (kindly 
provided by J Aoki, Kawasaki Medical School, Okayama, Japan) The transfected cells were 
selected with zeocin (500 ng/ml). Individual zeocin-resistant colonies were isolated by ring 
cloning and expanded sequentially in 24-well, 6-well and 60-mm plates. Expression of ATX 
protein was confirmed by immunoblotting. The ATX-positive clones were maintained as stable 
lines in RPMI (Gibco) supplemented with 10% fetal bovine serum (Gibco) and 2% 
penicillin/streptomycin (BioWhittaker). SKOV3-Zeo and SKOV3-ATX clonal cell lines were 
cultured under 5% CO2 at 37°C with routine passage every 2-3 days. LPA standards (14:0, 16:0, 
17:0, 18:0, 18:1, 20:4) were purchased from Avanti Polar Lipids (Alabaster, AL, USA). 
Ammonium formate (Fluka) were purchased from Sigma-Aldrich (St. Louis, MO, USA).  HPLC 
grade methanol, HPLC grade chloroform and ACS grade formic acid (EMD Chemicals) were 
purchased from VWR (Bridgeport, NJ, USA).  Cellular Proliferation Reagent WST-1 was 
purchased from Roche (Indianapolis, IN, USA). 
 
2.2  HPLC ESI-MS/MS Conditions 
 LPA subspecies were separated using a Kinetex 2.6u C18 100Å 50 x 2.1 mm reverse 
phase column on a Shimadzu 20-AD Series HPLC and subjected to mass spectrometric analysis 
using a ABSCIEX 4000 QTRAP. Mass spectrometry parameters were as follows: Polarity-
Negative, Ion Source: Electrospray, Q1 Resolution: Low, Q3 Resolution: Unit, Collision 
Activated Dissociation: High, MCA: No, Curtain Gas: 15.0 psi, Ion Source Temperature: 
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400.0°C, Nebulizer Gas: 30.0 psi, Turbo Gas: 70.0 psi, Interface Heater: On, Ion Spray Voltage - 
4500.0 V, Collision Cell Exit Potential: -9.0. MRM transitions with corresponding declustering 
potentials, collision energies and collision exit potentials are listed in Table 3. 
  HPLC conditions were as follows: Total Flow: 300 µl/min, Injection Volume: 10 µl, 
Column Oven: 50.0°C. Solvents for reverse phase HPLC separation were: Solvent A, 58:41:1 
methanol:water:formic acid and solvent B, 99:1 methanol:formic acid. Both solvents contained 5 
mM ammonium formate. Solvent conditions for HPLC separations were: 100% Solvent A from 
0-1 minute, linear increase in minutes 1-7 from 100% Solvent A to 100 % Solvent B, 100% 
Solvent B from minutes 7-8, immediate switch from 100% Solvent B to 100% Solvent A at 
minute 8, 100% A for minutes 8-10. 
 
2.3 1% FBS Experiments 
 SKOV3-Zeo, SKOV3-ATX, DOV13-Zeo, and DOV13-ATX cells were plated in 10 cm 
dishes and grown to 80% confluency in 10% FBS supplemented RPMI. Cells were transferred to 
1% FBS supplemented media overnight. Media was aliquoted into glass screw-top vials and 
stored at -20°C  until HPLC ESI-MS/MS analysis and biological assays could be performed. 
Cells were harvested in 200 µl cold PBS. Results for HPLC ESI-MS/MS analysis were 
normalized to microgram protein from harvested cells using a Bradford assay. 
 
2.4 LPA Extraction Procedures 
 A modified Bligh-Dyer method was used to extract LPA from sample media. The 
extraction protocol was as follows: 100 µl of sample media, 1 ml chloroform, 500 µl methanol, 
250 µl dH2O and 100 fmol 17:0 LPA standard were combined, vortexed, sonicated, and then 
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centrifuged at 4000 rpm for 10 minutes. The aqueous (top) layer was transferred to a clean glass 
tube, dried and resuspended in 100 µl methanol for mass spectrometry analysis and  is 
represented as "Bligh-Dyer Aqueous". Organic (bottom) layer from the same extraction was 
transferred to a separate clean glass vial, dried and resuspended in 100 µl methanol for mass 
spectrometry analysis and is represented as "Bligh-Dyer Organic".  After a separate Bligh-Dyer 
extraction was performed, the aqueous and organic layers were combined, dried and resuspended 
in 100 µl methanol for mass spectrometry analysis and are represented as "Bligh-Dyer" 
 A modified Folch method was also utilized for LPA extraction. The protocol was as 
follows: 200 µl sample + 2.5 ml chloroform + 1.25 ml methanol + 250 µl dH2O and 100 fmol 
17:0 LPA standard were combined, vortexed, sonicated, and then centrifuged at 4000 rpm for 10 
minutes. The aqueous (top) layer was transferred to a clean glass tube, dried and resuspended in 
100 µl methanol for mass spectrometry analysis and is represented as "Folch Aqueous". Organic 
(bottom) layer from the same extraction was transferred to a separate clean glass vial, dried and 
resuspended in 100 µl methanol for mass spectrometry analysis and is represented as "Folch 
Organic".  After a separate Folch extraction was performed, the aqueous and organic layers were 
combined, dried and resuspended in 100 µl methanol for mass spectrometry analysis and are 
represented as "Folch" 
 
2.5 Cellular Migration Assay 
 Cellular migration was measured in transwell chambers (pore size 8.0 µm; Corning 
Incorporated, Corning, NY) according to protocol in previous literature.40 In short, transwells 
were coated with 0.1 mg/ml collagen and placed in lower chamber containing media from 1% 
FBS experiments detailed above. SKOV3-Zeo cells suspended in serum-free RPMI containing 
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0.1% fatty acid-free BSA were added to the upper chamber at 2.5  x 10
4
 cells/well. Cells were 
allowed to migrate for 6 hours under 5% CO2 at 37ºC. Top of insert filter surface was washed 
with PBS and then stained with 0.1% crystal violet in methonal for 10 minutes. Filter surface 
was washed three times with PBS, and non-migrated cells were removed from the top filter 
surface with a cotton swab. Migrated cells were stained by the crystal violet and counted under a 
microscope. 
 
2.6 Cellular Proliferation Assay 
 Cellular proliferation was measured using WST-1 based colorimetric assay. SKOV3-Zeo 
cells (5 x 10
5
) were plated in five six-well plates and allowed to attach for 12 hours. 12 hours 
after plating, WST-1 reagent (200 µl) was added to four wells of one plate for reading of 
baseline attachment of SKOV3-Zeo cells. WST-1 reagent was allowed to incubate for 1 hour and 
absorbance was read at 450 nm with blank media absorbance used as background subtraction. 
After allowing cells to attach to the plate overnight, wells were washed once with PBS and 2 ml 
of conditioned media from the 1% FBS experiments was added to wells. Absorbance at 450 nm 
was measured using WST-1 reagent at 36 and 48 hours post-baseline reading. Cellular 
proliferation was calculated by subtracting the absorbance of blank media and average 
absorbance of 12 hour baseline measurement. 
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Results 
 
3.1 Retention Time Markers and Linear Signal Response Show Increased HPLC ESI-
MS/MS Sensitivity for LPA Quantitation 
  
 Previous HPLC ESI-MS/MS methods have been limited in sensitivity allowing only for 
quantification of LPA from biological samples such as tissue, blood, plasma, or serum. The goal 
of this study was to produce an HPLC ESI-MS/MS method with a high degree of sensitivity to 
quantify LPA levels from cell culture. In this regard, distinct fragmentation patterns were 
required for determination of optimal mass spectrometer parameters for the detection of LPA 
subspecies (Figure 4). Quantitative optimization for the transition of precursor to product ions 
supplied the optimal ABSCIEX 4000 QTRAP parameters that are detailed in Table 3. There 
were three common product ions produced upon fragmentation of LPA subspecies: 79 m/z - 
representing the fragmentation of the phosphite (PO3
-3
) from the sn-3 position, 97 m/z - 
representing the fragmentation of the phosphate (PO4
-4
) from the sn-3 position, and 153 m/z - 
representing the cyclical glycerol backbone produced upon fragmentation. The 153 m/z product 
ion was chosen for method development as it is the product ion common to all subspecies that 
was produced with the highest intensity (Figure 4). 
 Reverse phase HPLC separation prior to ESI-MS/MS provided the ability to easily and 
accurately distinguish LPA subspecies in relation to specific retention times. Several HPLC 
solvent conditions were investigated for accurate separation. The traditional HPLC solvents for 
LPA analysis provided insufficient elution from the fused-core column and insufficient 
separation among subspecies (data not shown).37, 39, 41, 42 In order to increase sample throughput, 
the HPLC solvent system used by the Chalfant laboratory for sphingolipid analysis was 
investigated for LPA analysis. Multiple variations of HPLC solvent gradients for this system 
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were attempted, but the best separation was provided by the solvent system and gradient detailed 
in Figure 5. Distinct chromatograms were produced (Figure 6) to allow accurate identification of 
LPA species related to specific HPLC retention times (Table 3). Peak assignments were initially 
determined by the analysis of indicated LPA standards using the MRM transitions and mass 
spectrometry parameters detailed in Table 3. Since there are no commercially available standards 
for 18:2 LPA and 22:6 LPA, relative retention times were calculated based upon the retention 
times for experimentally validated standards.   
 To investigate the sensitivity limits of this novel HPLC ESI-MS/MS method, a standard 
mixture of 14:0 LPA, 16:0 LPA, 17:0 LPA, 18:0 LPA, 18:1 LPA and 20:4 LPA was analyzed in 
concentrations from 10 fmols to 1 pmol per injection, and the signal response was measured as 
the area under the peak. When the results were plotted as signal response versus LPA 
concentration, a linear relationship was generated with correlation coefficients above 0.999 
(Figure 7A). When the results were plotted as a log-log plot of signal response versus LPA 
concentration, a linear relationship was generated with correlation coefficients above 0.997 
(Figure 7B).  Intra-day and inter-day precision and accuracy of QC samples were within 
acceptable range (Table 4). The method produced a lower limit of quantitation (five times signal 
to noise ratio) of 10 fmol per injection for each chain length. This lower limit of quantitation 
represents a minimum of a five-fold increase in sensitivity from the most recent HPLC ESI-
MS/MS LPA method and fifteen-fold increase in the remaining mass spectrometric reports in the 
literature for LPA analysis.37,43 
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Figure 4: Fragmentation patterns are required for development of a mass spectrometric method 
for the analysis of LPA subspecies. Direct infusion of dilute standards into ABSCIEX 
4000QTRAP provides distinct fragmentation patterns of precursor to product ions for each LPA 
subspecies. The 153.0 m/z product ion represents the cyclical glycerol backbone produced by 
fragmentation of precursor LPA ions and is common to all LPA subspecies. The 153.0 m/z 
product ion is therefore used during MRM analysis. 
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Table 3: ABSCIEX 4000 QTRAP mass spectrometer settings and retention times for reverse 
phase chromatographic separation of LPA species as described in Materials and Methods. DP - 
declustering potential, CE - collision energy, EP - entrance potential.  
 
 
Precursor Ion 
(m/z) 
Product Ion 
(m/z) DP CE EP 
Retention Time 
(min) 
14:0 LPA 381.3 152.7 -70.0 -26.0 -11.0 5.47 
16:0 LPA 409.3 152.7 -60.0 -30.0 -12.0 6.44 
17:0 LPA 423.3 152.7 -80.0 -30.0 -11.0 6.81 
18:2 LPA 433.3 152.7 -80.0 -30.0 -10.0 6.14 
18:1 LPA 435.3 152.7 -80.0 -30.0 -10.0 6.67 
18:0 LPA 437.3 152.7 -60.0 -30.0 -12.0 7.15 
20:4 LPA 457.3 152.7 -70.0 -30.0 -12.0 6.20 
22:6 LPA 481.3 152.7 -70.0 -30.0 -12.0 6.14 
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Figure 5: A novel solvent system allows for reverese phase HPLC seperation of LPA subspecies 
at distinct retention times. A Kinetex 2.6u C18 100A 50 x 2.1 mm reverse phase column on a 
Shimadzu 20-AD Series HPLC provides optimal separation using the following HPLC 
parameters: Total Flow: 300 µl/min, Injection Volume: 10 µl, Column Oven: 50.0°C. Solvent 
conditions for reverse phase HPLC separation are: Solvent A, 58:41:1 methanol/water/formic 
acid and Solvent B, 99:1 methanol/formic acid. Both solvents will contain 5 mM ammonium 
formate. Solvent gradient for HPLC separation is: 100% Solvent A from 0-1 minute, linear 
increase in minutes 1-7 from 100% Solvent A to 100 % Solvent B, 100% Solvent B from 
minutes 7-8, immediate switch from 100% Solvent B to 100% Solvent A at minute 8, 100% A 
for minutes 8-10. 
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Figure 6: Retention time standards are required for unambiguous peak assignment in the 
quantitation of LPA species during reverse phase HPLC ESI-MS/MS analysis. An internal 
standard mixture of commercially available LPA standards produces distinct MRM 
chromatograms for 14:0 LPA, 16:0 LPA, 17:0 LPA, 18:1 LPA, 18:0 LPA and 20:4 LPA for the 
purpose of unambigious peak assignment during HPLC ESI-MS/MS data analysis.  
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Figure 7: The method of detection for LPA species shows a linear response in the range from 10 
fmol to 1 pmol for LPA standards. An internal standard mixture of 14:0 LPA, 16:0 LPA, 17:0 
LPA, 18:0 LPA and 20:4 LPA was made in concentrations varying from 10 fmol/injection to 1 
pmol/injection. (A) . The results were plotted as signal response (area under the peak) versus 
amount standard in fmol/injection.  Data is the average of four separate sample injections ± 
SEM. (B) The results were plotted as log10 of signal response (area under the peak) versus log10 
fmol of standard per injection in a log-log plot. Data is the average of four separate sample 
injections ± SEM. 
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Table 4: Intra-day and Inter-day Precision and Accuracy  
Nominal
LPA Species Concentration (nM) Mean (n = 4) (nM) Mean accuracy (%) CV (%) Mean (n = 4 days) (nM) CV (%)
14:0 LPA 20 20.7 103.7 2.3 21.4 7.0
40 41.8 104.5 6.8 42.1 10.0
80 85.4 106.7 2.7 81.9 8.1
100 101.8 101.8 10.3 98.4 11.7
16:0 LPA 20 21.4 107.2 3.3 20.5 8.8
40 40.6 101.5 5.8 41.4 7.5
80 75.1 93.8 4.9 76.0 7.2
100 96.9 96.9 7.1 97.2 8.3
17:0 LPA 20 21.7 108.7 6.6 21.7 4.8
40 42.3 105.9 4.1 42.4 6.1
80 80.1 100.1 6.3 81.8 5.5
100 103.4 103.4 3.2 101.0 6.6
18:1 LPA 20 20.7 103.3 1.9 20.6 9.3
40 39.8 99.4 5.5 41.2 5.6
80 76.3 95.4 3.8 82.0 6.9
100 95.8 95.8 3.6 103.9 8.3
18:0 LPA 20 22.3 111.7 4.1 21.6 6.4
40 43.5 108.7 3.5 42.1 5.6
80 79.9 99.9 3.7 82.5 4.3
100 100.3 100.3 3.9 100.2 4.7
20:4 LPA 20 21.4 107.2 10.3 20.0 11.7
40 40.4 101.1 5.6 41.3 10.7
80 75.2 94.1 6.0 83.2 10.6
100 91.2 91.2 3.0 99.3 9.8
Inter-day precisionIntra-day precision and accuracy
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3.2 Non-acidified Extraction Methods Produce Quantifiable LPA Levels Without LPC 
Degradation 
 
Most reported HPLC ESI-MS/MS methods for quantitation of LPA have relied on 
extraction methods that required highly acidic treatments. These acidic conditions may 
contribute to the artificial conversion of LPC to LPA, and thereby lead to LPA measurements 
that are not characteristic of actual sample levels.36, 39 To address this issue, a number of 
extraction techniques without acidic treatment were tested on conditioned media samples. First, a 
direct media sample injection into the HPLC following polarity adjustment to starting HPLC 
conditions was tested. This extraction method proved to be insufficient due to a lack of sample 
concentration step during extraction (data not shown). Next, a simple lysophospholipid 
extraction that consists of a single methanol solvent dilution and single step of centrifugation was 
utilized as previously reported.44 While this extraction was suitable for LPA extraction of in vivo 
samples, it was unsuccessful at providing sufficient recovery of the minute levels of LPA from in 
vitro samples because this protocol also lacked a sample concentration step (data not shown). A 
solid-phase extraction protocol utilizing a reversed phase silica based column was also tested but 
did not provide sufficient results due to an inability to efficiently remove LPA from the column 
during the final elution step (data not shown). Finally, two non-acidified liquid-liquid extractions 
termed modified Bligh-Dyer and modified Folch extractions were tested and showed to provide 
reliable recovery of LPA at levels above the limits of quantitation (Figure 8). Importantly, the 
Folch extraction technique demonstrated a more reliable recovery of LPA with the combined 
organic and aqueous fractions approximately equaling the total Folch recovery (Figure 8). 
Therefore, the total Folch extraction was used throughout the remainder of the manuscript due to 
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its consistent recovery, simple protocol, and lack of producing artificial LPA contamination 
under acidic conditions. 
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Figure 8: Non-acidic extraction methods for in vitro LPA quantitation show that organic-
aqueous phase break protocols provided sufficient recovery for HPLC ESI-MS/MS analysis for 
1% FBS overnight treated DOV13-Zeo cells. BD - combined layers of Bligh-Dyer, BD Aqueous 
- aqueous layer of Bligh-Dyer, BD Organic- organic layer of Bligh-Dyer, Folch - combined 
layers of Folch, Folch Aqueous - aqueous layer of Folch, Folch Organic - organic layer of Folch. 
Extraction protocols are detailed in Materials and Methods. Data represents n = 3 ± SEM.  
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3.3 Autotaxin Overexpression Induces an Increase in Specific LPA Species  
  
 With the optimal extraction procedure for LPA determined, the protocol was fully 
operational for validation using biological applications. In this regard, we chose to examine the 
production of LPA in autotaxin-overexpressing cells as compared to vector control cells. Since 
ovarian cancer has been widely established to have increased LPA dysregulation, ovarian cancer 
cell lines SKOV3 and DOV13 and their corresponding autotaxin clones were analyzed. Figure 
9A shows that the 16:0, 18:1, 18:2, 18:0, and 20:4 LPA subspecies were significantly increased 
in the media from SKOV3-ATX cells, but importantly, the 22:6 LPA subspecies remained 
relatively unchanged. Similarly, comparison of LPA subspecies in media from  DOV13-Zeo and 
DOV13-ATX showed an increase in the 16:0, 18:1, and 18:0 LPA subspecies with little or no 
change among the 14:0, 20:4, and 22:6 LPA subspecies (Figure 10A). Hence, autotaxin increases 
the levels of specific chain lengths of LPA. Furthermore, the total levels of LPA increased two-
fold in media from autotaxin-overexpressing cells in both cell lines studied, as indicated in 
Figures 9B and 10B. 
 Prior to the development of this HPLC ESI-MS/MS method for quantitation of LPA from 
cell culture, quantitation of LPA production have relied on comparisons to the effect of 
exogenously introduced LPA on biological assays such as cellular migration and 
proliferation.40
,45 Therefore, the observed increases in LPA levels produced by autotaxin 
overexpression as assayed by HPLC ESI-MS/MS were compared to the biological effect of these 
increased levels of LPA cellular migration and proliferation. Specifically, media from either 
SKOV3-Zeo or SKOV3-ATX was used as a chemoattractant in cellular migration assays. Media 
from SKOV3-ATX produced a two-fold increase in cellular migration when compared to media 
from SKOV3-Zeo, which correlated to the increase in LPA levels measured by HPLC ESI-
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MS/MS (Figure 11). To further validate the increase in LPA levels in SKOV3-ATX media, the 
effect of SKOV3-ATX and SKOV3-Zeo media on cellular proliferation was measured. Media 
from autotaxin overexpressing cells induced an increased in cellular proliferation as compared to 
SKOV3-Zeo media, which also correlated to the total increase in LPA levels measured by HPLC 
ESI-MS/MS (Figure 12).  
 Migration and proliferation studies were also done with conditioned media from DOV13-
Zeo and DOV13-ATX cells to validate the HPLC ESI-MS/MS analysis detailed in Figure 10. 
The approximate two-fold increase of cellular migration of SKOV3-Zeo cells using conditioned 
media from DOV13-Zeo and DOV13-ATX as chemoattractants correlated to the two-fold 
increase of total LPA levels as determined by HPLC ESI-MS/MS analysis (Figure 13). However, 
the SKOV3-Zeo cellular proliferation assays using conditioned media from DOV13-Zeo and 
DOV13-ATX showed no increase in cellular proliferation (Figure 14). This result shows that the 
HPLC ESI-MS/MS method developed in this study is superior to biological assays currently in 
use. 
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Figure 9: Comparison of control vector SKOV3 cells versus autotaxin-overexpressing clones 
show increased levels of LPA in autotaxin-overexpressing cell lines. (A) HPLC ESI-MS/MS 
analysis of LPA subspecies shows increases in 16:0, 18:2, 18:1, 18:0, and 20:4 LPA levels, but 
not 22:6 LPA. Data represents n = 3 ± SEM. (B) HPLC ESI-MS/MS analysis detailed in (A) 
shows an approximate two-fold increase in total LPA levels between control vector and 
autotaxin-overexpressing cells. Data represents n = 3 ± SEM. p-values were calculated as 
student's t-test using SigmaPlot v. 12.0 (SyStat). 
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Figure 10: Comparison of control vector DOV13 cells versus autotaxin-overexpressing clones 
show increased levels of LPA in autotaxin-overexpressing cell lines. (A) HPLC ESI-MS/MS 
analysis of LPA subspecies shows increases in 16:0, 18:1, 18:0, and 20:4 LPA levels, but not 
14:0 or 22:6 LPA. Data represents n = 3 ± SEM. (B) HPLC ESI-MS/MS analysis detailed in (A) 
shows an approximate two-fold increase in total LPA levels between control vector and 
autotaxin-overexpressing cells. Data represents n = 3 ± SEM. 
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Figure 11: Conditioned media from SKOV3 autotaxin-overexpressing clones correspond to 
increased cellular migration of SKOV3-Zeo cells when compared to conditioned media from 
control vector cell lines. Media from overnight 1% FBS experimental protocol was used as a 
chemoattractant for cellular migration assay as detailed in Materials and Methods. (A) Images of 
migrated cells show increased SKOV-Zeo cellular migration using conditioned media from 
autotaxin-overexpressing cell line. (B) Calculations show that increases in migration correspond 
to total LPA levels measured by HPLC ESI-MS/MS analysis. Data represents n = 4 ± SEM. p-
values were calculated as student's t-test using SigmaPlot v. 12.0 (SyStat).  
SKOV3 –
Zeo Media
SKOV3 –
ATX Media
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Figure 12: Conditioned media from SKOV3 autotaxin-overexpressing clones is associated with 
increased SKOV3-Zeo cellular proliferation when compared to conditioned media from control 
vector cell line. (A) Images of cell growth at corresponding time points show increased SKOV-
Zeo cellular proliferation. (B) Calculations show that increases in proliferation correspond to 
total LPA levels measured by HPLC ESI-MS/MS analysis. Data represents n = 5 ± SEM. p-
values were calculated as student's t-test using SigmaPlot v. 12.0 (SyStat). 
SKOV3 –
Zeo
Media
SKOV3 –
ATX 
Media
36 Hour 48 Hour
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Figure 13: Conditioned media from DOV13 autotaxin-overexpressing clones correspond to 
increased cellular migration of SKOV3-Zeo cells when compared to conditioned media from 
control vector cell lines. (A) Images of migrated cells show increased SKOV-Zeo cellular 
migration using conditioned media from autotaxin-overexpressing cell line. (B) Calculations 
show that increases in migration mimic the increased total LPA levels measured by HPLC ESI-
MS/MS analysis. Data represents n = 4 ± SEM. p-values were calculated as student's t-test using 
SigmaPlot v. 12.0 (SyStat). 
DOV13 –
Zeo Media
DOV13 –
ATX 
Media
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Figure 14: Conditioned media from DOV13 autotaxin-overexpressing clones does not 
correspond to increased SKOV3-Zeo cellular proliferation when compared to conditioned media 
from control vector cell line. (A) Images of cell growth at corresponding time points show no 
increase in SKOV-Zeo cellular proliferation. (B) Calculations show that, unlike SKOV3-ATX 
conditioned media, DOV13-ATX conditioned media does not cause an increase in SKOV13-Zeo 
cellular proliferation. Data represents n = 5 ± SEM. p-values were calculated as student's t-test 
using SigmaPlot v. 12.0 (SyStat).  
DOV13 –
Zeo
Media
DOV13 –
ATX 
Media
36 Hour 48 Hour
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Discussion  
 
4.1 Necessity for this Novel HPLC ESI-MS/MS Method 
 The few reported methods for measuring endogenous LPA in vitro have suffered from a 
multitude of problems, such as inability to distinguish LPA species, a labor intensive nature, and 
high limits of detection. For example, some previous studies have even relied on thin-layer 
chromatography for pre-separation, a highly labor intensive and mainly qualitative protocol, for 
measuring autotaxin activity and subsequent LPA production in vitro.38 Recently, HPLC ESI-
MS/MS has been established as a reliable method for LPA quantitation from biological samples, 
but the significant limitations of these methods have made in vitro analysis unfeasible. In this 
study, we have developed a HPLC ESI-MS/MS method with increased sensitivity to resolve 
these issues and provide researchers the ability to make in vitro LPA quantitation possible in 
conjunction with quantitative measurements of other lipid classes.  
  
4.2 Advantages of HPLC Conditions Utilized in this Study 
 Prior to this study, many of the publications utilizing HPLC ESI-MS/MS method 
development for LPA measurement suffer from undesirable HPLC conditions. For example, one 
report demonstrated what was termed "unidentified peaks" during chromatographic separation.37 
The HPLC conditions reported here allow for a more reliable identification of LPA species by 
the elimination of these unidentifiable peaks. This HPLC method also does not utilize 
undesirable solvent conditions. For example, the highly acidic solvents used by some methods 
may result in on-column degradation of LPA and artificial conversion of LPC to LPA.35 Also, the 
highly organic solvents reported by other groups can affect the lifetime of the HPLC seals and 
are not functional for analysis of other lipid classes in the same sample run.36,39 Use of such lipid 
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class specific HPLC methods significantly reduces the amount of data acquired from a single 
sample. The solvent system used in this study has previously been established for the study of 
sphingolipids, particularly ceramide, ceramide-1-phosphate, sphingosine, and sphingosine-1-
phosphate.46 Other HPLC solvent systems reported for LPA, including the most recent HPLC 
ESI-MS/MS method with highest sensitivity until this report, have the potential for ion 
suppression due to the inclusion of triethyl ammonium acetate as a modifier.43 This suppression 
will produce the requirement of regular and thorough cleaning of the instrument before further 
analysis of other lipid classes. The need to change solvent systems to analyze the different lipid 
species also significantly increases valuable instrument time, thereby decreasing sample 
throughput. The HPLC ESI-MS/MS method in this study also utilizes solvent conditions that do 
not cause contamination and are capable of being used for sphingolipid analysis. Hence, this new 
HPLC ESI-MS/MS method for LPA not only overcomes the undesirable HPLC conditions but 
also uses chromatographic separation that allows for other lipids to be efficiently analyzed 
during the same sample run. 
  
4.3 Advantages of LPA Extraction Method Utilized in this Study 
 An easy and reliable extraction method for LPA analysis was determined. Prior to this 
study, numerous extraction protocols have been published for the separation of LPA from 
biological samples, but early methods used thin-layer chromatographic separation as the initial 
basis of separation, and subsequent protocols have utilized a modified form of Bligh-Dyer lipid 
extraction where the optimal recovery is obtained using highly acidic conditions.37,38 These acidic 
conditions have been shown to cause conversion of LPC to LPA during extraction and thereby 
provide inaccurate and artificial measurements.36,47 Water-saturated butanol liquid-liquid 
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extraction methods have proven to be efficient, but are quite labor intensive.39
,47. The extraction 
method utilized in this study is a simple, efficient, organic-aqueous phase break separation that 
requires minimal labor, minimizes artificial LPA measurements, and provides sufficient recovery 
for LPA quantitation. 
  
4.4 Increased Sensitivity Provides the Ability for Quantitation of in vitro LPA Levels 
 The method described herein provides a highly sensitive assay for the quantification of 
LPA levels from in vitro experiments. An increase in HPLC ESI-MS/MS sensitivity was 
necessary to quantify LPA subspecies levels from in vitro samples as other in vitro LPA 
quantitation methods had significant sensitivity limitations. The most sensitive HPLC ESI-
MS/MS method previously reported for LPA subspecies quantitation has a lower limit of 
quantitation of 54 femtomoles on-column.43 The method described in this study achieves a lower 
limit of quantitation of 10 femtomoles on-column . Hence, this represents a five-fold increase in 
sensitivity levels for HPLC ESI-MS/MS analysis. Furthermore, other reported studies could only 
assay one subspecies of LPA even when attempting to artificially induce LPA production by 
LPC treatment.48 This reported method also suffered from the same acidic extraction conditions 
as previously published protocols, limiting even conclusions for this one LPA subspecies.48 The 
increased sensitivity of the HPLC ESI-MS/MS method developed in this study will provide 
researchers with the ability to easily and accurately quantify all LPA subspecies levels in vitro. 
Furthermore, the method described in this study was the first to be validated by traditional 
biological assays. 
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4.5 Conclusions and Future Directions 
 Measurement of LPA in vitro has proven to be unreliable until the development of the 
HPLC ESI-MS/MS method described herein. Previous HPLC ESI-MS/MS methods have 
focused on biological samples, which contain high levels of LPA, and which have also suffered 
from unfavorable HPLC conditions, hazardous and inaccurate extraction protocols, and 
inadequate sensitivity levels. This new HPLC ESI-MS/MS method will offer researchers a 
valuable tool for determination of the activities of LPA subspecies for the purpose of delineating 
biological mechanisms and pre-clinical drug development for diseases such as diabetes, 
atherosclerosis, and cancer. The increased sensitivity levels will also provide clinicians with 
better ability to quantitate LPA with the goal of early detection of disease states. Overall, the 
HPLC ESI-MS/MS method presented in this study supplies a new tool for further exploration of 
the biological functions of LPA.   
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